Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Onercept evaluated for use in moderate-to-severe Crohn's disease
September 20th, 2006
A study from Belgium has reported on the evaluation of onercept for use in moderate-to-severe Crohn disease (CD). "Onercept is a recombinant, soluble human p55 receptor to tumor necrosis factor-alpha. A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of onercept induction therapy in patients with CD," wrote P. Rutgeerts and colleagues, University Hospital Gasthuisberg. "Patients (n=207) with moderate-to-severe acute or chronic active CD were randomized to receive subcutaneous onercept (10, 25, 35, or 50 mg) or placebo 3 times weekly for 8 weeks. Primary analysis was induction of remission...
Source: Biotech Week (2006-09-20)
|
